Biotech Values

[Mpower]

in light of what was said at the recent conference call, we can extrapolate reimburseable expenses to a reasonable certainty. (This analysis has been previously posted on iHub, so I won't go there...)

That being said, the PPS moving below pre-approval levels is quite curious and out-of-line with a worst case scenario (TEVA approval and AG)